Ascrinvacumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A human immunoglobulin G2 (IgG2) monoclonal antibody against activin receptor-like kinase-1 (ALK-1; ALK1), with potential anti-angiogenic and antineoplastic activities. Upon administration, ascrinvacumab targets and binds to ALK-1, and prevents ALK-1 activation by its ligands bone morphogenetic protein 9 (BMP) 9 and BMP10. This prevents ALK-1-mediated endothelial cell signaling and the activation of transforming growth factor-beta (TGF-beta)/TGF-beta receptor I (ALK-5) signaling. This inhibits tumor blood vessel growth, reduces blood flow and angiogenesis and leads to an inhibition of tumor cell proliferation and modulation of the tumor microenvironment (TME). ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor cell types and increases endothelial cell proliferation and migration.

**Synonyms:** - ASCRINVACUMAB - Anti-ALK-1 Monoclonal Antibody GT90001 - Anti-Activin Receptor-like Kinase 1 Monoclonal Antibody PF-03446962 - Anti-Activin Receptor-like Kinase-1 Monoclonal Antibody GT90001 - GT 90001 - GT-90001 - GT90001 - PF 03446962 - PF-03446962 - PF03446962